<code id='BB2B4DB77B'></code><style id='BB2B4DB77B'></style>
    • <acronym id='BB2B4DB77B'></acronym>
      <center id='BB2B4DB77B'><center id='BB2B4DB77B'><tfoot id='BB2B4DB77B'></tfoot></center><abbr id='BB2B4DB77B'><dir id='BB2B4DB77B'><tfoot id='BB2B4DB77B'></tfoot><noframes id='BB2B4DB77B'>

    • <optgroup id='BB2B4DB77B'><strike id='BB2B4DB77B'><sup id='BB2B4DB77B'></sup></strike><code id='BB2B4DB77B'></code></optgroup>
        1. <b id='BB2B4DB77B'><label id='BB2B4DB77B'><select id='BB2B4DB77B'><dt id='BB2B4DB77B'><span id='BB2B4DB77B'></span></dt></select></label></b><u id='BB2B4DB77B'></u>
          <i id='BB2B4DB77B'><strike id='BB2B4DB77B'><tt id='BB2B4DB77B'><pre id='BB2B4DB77B'></pre></tt></strike></i>

          leisure time

          leisure time

          author:fashion    Page View:21
          Priscilla Chan, left, with Shana Kelley and Gov. J.B. Pritzker of Illinois at the new CZ Biohub Chicago. Courtesy Dale Ramos/Chan Zuckerberg Initiative

          CHICAGO — At what point does inflammation, a key component of the body’s immune defense system, swerve out of control and start to drive disease?

          That’s the key question that a new research center, the Chan Zuckerberg Biohub Chicago, has been created to try to answer.

          advertisement

          The Chicago hub is the second one started by the Chan Zuckerberg Initiative, the philanthropic organization of Facebook founder Mark Zuckerberg and his wife, Priscilla Chan. The first hub, based in the Bay Area, has been investigating cell biology and infectious diseases, while this new one is homing in on inflammatory processes in tissues across the body.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          explore

          Bright Health sells Medicare Advantage business to Molina
          Bright Health sells Medicare Advantage business to Molina

          BrightHealthisofficiallyleavingthehealthinsurancemarket.ThecompanyhasagreedtosellitsMedicareAdvantag

          read more
          BioAge raises $170M for combination therapy with Zepbound
          BioAge raises $170M for combination therapy with Zepbound

          Illustration:STAT;Source:EliLilly/APACaliforniabiotechdevelopingacombinationtherapywiththeobesitydru

          read more
          How to save PrEP access — and even expand it
          How to save PrEP access — and even expand it

          UndertheAffordableCareAct,healthinsurersarerequiredtocoverallcostsassociatedwithpreventivecare—inclu

          read more

          The Readout: Abbvie and Humira, CRISPR in utero, Annovis Bio

          RubyWallauforSTATWanttostayontopofthescienceandpoliticsdrivingbiotechtoday? Signup togetourbiotechne